A lawsuit was filed on behalf of investors in Array Biopharma Inc (NASDAQ:ARRY) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 12/12/2017 -- An investor, who purchased NASDAQ:ARRY shares, filed a lawsuit against Array Biopharma Inc over alleged Securities Laws violations.
Investors who purchased shares of Array Biopharma Inc (NASDAQ:ARRY) should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The plaintiff alleges on behalf of purchasers of Array Biopharma Inc (NASDAQ:ARRY) common shares between December 16, 2015 and March 17, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 16, 2015 and March 17, 2017, the defendants issued materially false and/or misleading statements and/or failed to disclose that Array's NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma, that it was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutual melanoma, and that as a result of the foregoing, Array's public statements were materially false and misleading at all relevant times
Those who purchased shares of Array Biopharma Inc (NASDAQ:ARRY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels